Preclinical research suggests that interleukin-1–mediated inflammatory signalling is crucial for the maintenance of chronic myeloid leukaemia stem cells persisting after treatment with tyrosine kinase inhibitors.
Bosutinib elicits durable responses in chronic phase–chronic myeloid leukaemia patients who have failed prior treatment with multiple tyrosine kinase inhibitors, shows an updated analysis of an ongoing phase I/II trial.
A worldwide network of nonprofit organisations supporting patients with chronic myeloid leukaemia and their families has made key recommendations to address concerns regarding the use of generic forms of tyrosine kinase inhibitors.
Ultra-deep sequencing can detect the T315I tyrosine kinase inhibitor resistance mutation in patients with chronic myeloid leukaemia several months before conventional sequencing, study findings suggest.
Treatment with tyrosine kinase inhibitors prior to and after allogeneic haematopoietic stem cell transplantation may improve outcomes in children presenting with an advanced stage of chronic myeloid leukaemia, suggests a case series.
Monitoring early changes in ABCB1 messenger RNA expression could identify chronic phase chronic myeloid leukaemia patients likely to respond poorly to tyrosine kinase inhibitor treatment, shows a post hoc analysis of a phase II trial.
Dasatinib has durable efficacy and manageable toxicity in the long-term treatment of patients with chronic-phase chronic myeloid leukaemia that is resistant or intolerant to imatinib, shows final analysis of the CA180-034 trial.
A review of tyrosine kinase inhibitor therapy in Japanese patients with chronic myeloid leukaemia demonstrates high rates of treatment response and good outcomes but highlights the various issues associated with treatment discontinuation.
Patients treated for chronic myeloid leukaemia have a higher risk of arterial and venous vascular events than their counterparts in the general population, suggest the results of a Swedish cohort study.
Research demonstrates the continuing role of allogeneic stem cell transplantation as a salvage option for patients with chronic myeloid leukaemia who progress to accelerated phase or blast crisis after tyrosine kinase inhibitor failure.
Patients with high-risk chronic myeloid leukaemia who undergo allogeneic haematopoietic stem cell transplantation may benefit from continuing with tyrosine kinase inhibitor therapy, US clinicians believe.